The fact that TLR2/6 agonists can reduce virus levels in the upperrespiratory tract has motivated the recent investigation of the useof a Pam2Cys analogue in the treatment of COVID-19 causedby the SARS-Cov-2 virus.128 Intranasalprophylactic administration of a compound INNA-051, a PEGylated Pam2Cys analogue (structure not disclosed but related to thatshown in ref (110)),was shown to reduce SARS-CoV-2 transmission and to provide protectionagainst COVID-19. The gene discussed is TLR2; the disease is COVID-19.